Skip to main content
Erschienen in: Esophagus 4/2017

Open Access 05.09.2017 | Special Article

Descriptive Rules for Achalasia of the Esophagus, June 2012: 4th Edition

verfasst von: Japan Esophageal Society

Erschienen in: Esophagus | Ausgabe 4/2017

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Review Committee for Descriptive Rules for Achalasia of the Esophagus
President
Hisahiro Matsubara
Former President
Nobutoshi Ando
English Edition Committee, Chairman
Nobuo Omura
Adviser
Hideyuki Kashiwagi
English Edition Committee Members
Soji Ozawa
Surgery
Tatsuyuki Kawano
Surgery
Hiroyasu Makuuchi
Surgery
Katsuhiko Iwakiri
Internal Medicine
Motoyasu Kusano
Internal Medicine
Ken Haruma
Internal Medicine
Kaiyo Takubo
Pathology
Akio Yanagisawa
Pathology
Japanese Edition Committee, Chairman
Hideyuki Kashiwagi
Contents
Descriptive Rules for Achalasia of the Esophagus
I.
Achalasia of the Esophagus
1.
Definition
 
2.
Symptoms
 
3.
Diagnosis
3.1
Diagnostic features on esophagography
 
3.2
Diagnostic features on upper gastrointestinal endoscopy
 
3.3
Diagnostic features on esophageal manometry
 
 
4.
Classification
4.1
Radiographic images of the esophagus
 
4.2
Endoscopy
 
4.3
Esophageal manometry
 
4.4
Histopathology
 
 
5.
Treatment
5.1
Pharmacotherapy
 
5.2
Endoscopic treatment
 
5.3
Surgical treatment
 
 
 
II.
Other Esophageal Motility Disorders
1.
Diffuse esophageal spasm (DES)
 
2.
Nutcracker esophagus
 
3.
Hypertensive LES
 
4.
Non-specific esophageal motility disorder (NEMD)
 
5.
Esophageal motility dysfunctions complicating other diseases
 
6.
Pseudoachalasia
 
 
I Achalasia of the esophagus
1. Definition
Achalasia of the esophagus is an esophageal motility disorder of unknown etiology, characterized by failure of relaxation of the lower esophageal sphincter (LES) and impaired peristaltic movement of the lower esophageal body.
2. Symptoms
Symptoms include dysphagia, regurgitation of ingested food into the oral cavity, chest pain, weight loss, and nocturnal cough.
3. Diagnosis
Useful diagnostic modalities for this disorder include: (1) esophagography; (2) upper gastrointestinal endoscopy; (3) esophageal manometry; (4) histopathologic examination of the esophageal muscle layers (in patients undergoing surgery).
3.1 Diagnostic features on esophagography
1.
Dilatation/tortuosity of the esophagus
 
2.
Retained food in the esophagus and poor emptying of barium
 
3.
Smooth conical narrowing of the esophagogastric junction (bird-beak sign)
 
4.
Absence or diminution of gastric air bubbles
 
5.
Abnormal esophageal motility
 
3.2 Diagnostic features on upper gastrointestinal endoscopy
1.
Dilatation of the esophageal lumen
 
2.
Abnormal retention of food and/or liquid remnants in the esophagus
 
3.
Whitish change and thickening of the esophageal mucosal surface
 
4.
Functional stenosis of the esophagogastric junction (endoscope passes through the stenotic segment although the esophagogastric junction fails to be dilated by insufflation; the procedure may involve winding of tissue around the scope or leafing of tissue on scope rotation)
 
5.
Abnormal contraction waves of the esophagus
 
3.3 Diagnostic features on esophageal manometry
1.
Deglutitive dysrelaxation of the LES*
 
2.
Disappearance of primary peristaltic waves*
 
3.
Increased esophageal static pressure (higher than the intragastric pressure)
 
4.
Increased LES pressure
 
5.
Occurrence of simultaneous contraction waves
 
*Principal finding
4. Classification
4.1 Radiographic images of the esophagus
X-ray examination: a dorsoventral view is obtained with the patient in the standing position; the patient is asked to swallow a barium meal, consisting of 100 mL of 100% barium sulfate, as quickly as possible, so that radiograms can be obtained within 1 min of the swallowing. No spasmolytic agent is used.
(1)
Morphologic type
 
This classification is based on the radiographic features of the esophagus. This classification, subclassified into the spindle type, flask type and sigmoid type according to the conventional descriptive rules, has been extensively used over decades. However, there are no distinct pathophysiological differences between the spindle type and the flask type, and no distinction is made between these two types in the United States or Europe. As for the sigmoid type, the extent of deviation and tortuosity of the upper esophagus may also have an impact on the therapeutic outcome. Therefore, achalasia is classified into the following two types in this version of the descriptive rules.
i.
Straight (St) type (Fig. 1)
Modest degree of tortuosity of the longitudinal axis of the esophagus. This type includes the conventional spindle type and flask type mentioned above.
 
ii.
Sigmoid (Sg) type (Fig. 2)
Significant degree of tortuosity of the longitudinal axis of the esophagus. Pronounced rightward tortuosity of the esophagus, causing the organ to assume an L-shaped course, is specifically termed the advanced sigmoid (aSg) type (Fig. 3).
 
Addendum:
The St type, Sg type, and aSg type are illustrated in Fig. 4.
In cases where esophageal flexion(s) is noted, a straight line should be drawn in the direction of the esophageal long axis.
In case two straight lines are drawn, a single angle will be formed by the crossing straight lines; in case three straight lines are drawn, two angles will be formed by the crossing straight lines.
The following definitions are framed in order of increasing angle, α, formed by the crossing straight lines.
When α ≥ 135°, the disorder is diagnosed as the St type.
When 90° ≤ α < 135°, the disorder is diagnosed as the Sg type.
When α < 90°, the disorder is diagnosed as the aSg type.
The angle(s) should be stated without fail.
(2)
Dilatation grading (Fig. 5)
 
The dilatation is classified into Grades I to III according to the maximum transverse diameter (d) of the esophagus drawn perpendicularly to the longitudinal axis.
i.
Grade I d < 3.5 cm
 
ii.
Grade II 3.5 ≤ d < 6.0 cm
 
iii.
Grade III 6.0 cm ≤ d
 
Addenda:
i.
Tortuosity of the upper thoracic esophagus (Fig. 6)
 
ii.
Leftward-tortuous esophagus (Fig. 7)
 
iii.
Concurrent epiphrenic diverticulum (pulsion diverticulum) (Fig. 8)
 
iv.
Concurrent carcinoma of the esophagus (location, size, and depth of invasion should be stated)
 
4.2 Endoscopy (Fig. 9)
Achalasia of the esophagus is classified into the following four types according to the endoscopic findings.
i.
Normal type: there is no obvious retention of ingested food or dilatation of the esophagus.
 
ii.
Retained type: retention of ingested food or fluid in the esophagus, but no apparent dilatation.
 
iii.
Dilated type: dilatation of the esophagus is evident, but no retained ingested food is seen in the esophagus.
 
iv.
Retained-dilated type: the esophagus is dilated with retained ingested food.
 
Reference findings suggestive of achalasia (Fig. 10)
In healthy subjects who inspire deeply, the lower esophagus usually opens, and an entire view of the esophageal palisade vessels becomes visible. However, in patients with achalasia, an entire view of the esophageal palisade vessels does not become visible and, in addition, rosette-like esophageal folds appear in the lower esophagus [1].
4.3 Esophageal manometry
Achalasia of the esophagus is classified into the following two types according to the findings on esophageal manometry.
i.
Complete type
Impaired relaxation of the LES and the absence of esophageal peristalsis in response to swallowing.
 
ii.
Incomplete type
Not meeting the above criteria.
 
Esophageal manometric findings in healthy subjects (Fig. 11a, b)
Esophageal manometric findings in patients with achalasia (Fig. 12, b)
(1)
Impaired relaxation of the LES
 
(2)
Absence of esophageal peristalsis
 
Addendum:
i) Vigorous achalasia [2] (Fig. 13a, b)
In addition to the above diagnostic criteria, when amplitude of the lower esophagus is ≥37 (30 to 40) mmHg, this condition is defined as vigorous achalasia, and when amplitude of the lower esophagus is <37 (30 to 40) mmHg, it is termed classic achalasia.
4.4 Histopathology (Figs. 14, 15)
It is advisable for evaluation of the esophageal muscularis propria to be performed both on specimens from the dilated segment and narrowed segment. The tissue sampling sites must be stated. Achalasia of the esophagus is classified under the following three categories according to the ganglion cell/nerve fiber status observed on histopathology.
1.
Grade I: practically normal ganglion cells and nerve fibers.
 
2.
Grade II: diminution and degeneration of ganglion cells and nerve fibers.
 
3.
Grade III: loss of ganglion cells and nerve fibers.
 
Addendum: note if there is any lymphocytic infiltration, etc.
5. Treatment
5.1 Pharmacotherapy [310]
Calcium channel antagonists (e.g., Adalat® Capsule) and nitrates (e.g., Nitorol® Tablet) are used as drugs to relax the LES. In patients with pronounced subjective symptoms, complete relief of the symptoms can often not be obtained with pharmacotherapy alone. Currently, pharmacotherapy is generally recognized as the treatment option of choice for patients with mild disorder and for those who are not suitable candidates for endoscopic therapy or surgery, as well as for temporary relief of symptoms. The medications are also prescribed as needed in case of postoperative chest pain. Calcium antagonists are subject to off-label use in terms of national health insurance scheme.
5.2 Endoscopic treatment
(1) Dilatation therapy [1113]
Following endoscopic insertion of a guidewire into the stomach, a balloon (usually, a 30-mm balloon) is placed at the gastroesophageal junction along the guidewire under fluoroscopic guidance; the balloon is then gradually inflated, beginning at a low pneumatic pressure level, while checking for pain until the balloon notches disappear. The pneumatic pressure is further elevated slightly to dilate the balloon while checking for pain, although excessive pressurization may be risky. The reported effectiveness rates of balloon dilatation range from 66 to 93%, hence virtually comparable to effectiveness rates of surgical treatment. However, the reported effectiveness rates of balloon dilatation in young adults (under 40 years of age) are poorly responsive to treatment. Symptoms recur in about 33% of patients at 4 to 6 years after balloon dilatation. Complications include reflux esophagitis, chest pain, fever, and perforation.
The conditions and frequency of balloon dilatation should be stated in each case of dilatation therapy.
(2) Botulinum toxin local injection therapy [14, 15]
Botulinum toxin local injection reduces in the LES pressure via inhibiting neurotransmitter release from the preganglionic cholinergic neurons. In botulinum toxin local injection therapy, 100 IU of type A botulinum toxin is injected endoscopically into the 4 quadrants of the LES. Relapse is often reported in 6–12 months. Use of botulinum toxin local injection therapy for achalasia cardia is subject to off-label use for the purpose of coverage by the national health insurance scheme in Japan.
(3) Endoscopic myotomy [16]
This procedure consists of peroral endoscopic myotomy performed on the esophageal submucosa. Use of endoscopic myotomy for the treatment of achalasia cardia is listed as off-label use for the purpose of coverage by the national health insurance scheme.
5.3 Surgical treatment [1724]
Surgical treatment [1724]
Surgical treatment was previously performed via a laparotomy, and the procedure has recently become supplanted by a laparoscopic technique. Heller’s myotomy to relieve obstruction combined with a reflux-preventive procedure to prevent post-myotomy gastroesophageal reflux, especially the Dor technique, is widely used, with gratifying response rates of as high as about 90%.
The length of muscle layer incision, whether the short gastric arteries vessels were dissected or not, whether an esophageal bougie was inserted during the operation or not, and whether there was any intraoperative mucosal injury or not should be stated.
II Other Esophageal Motility Disorders [2530]
1. Diffuse esophageal spasm (DES) (Figs. 16, 17, 18)
DES is a motility disorder characterized by occasional, persistent or repetitive abnormal contractions while peristaltic waves are usually normal, and may cause dysphagia and chest pain. One of the diagnostic criteria is that 2 or more repetitive simultaneous contractions account for 20% or more of the peristalsis on water swallow. The abnormality may be accompanied with multi-peaked contractions, elevation of the amplitude of the peristaltic waves, spontaneous contractions, and incomplete LES relaxation. Esophageal X-ray findings may include simultaneous contractions (nonperistaltic contractions), corkscrew appearance, arrest of contrast medium passage, and pocket formation.
2. Nutcracker esophagus (Figs. 19, 20)
Nutcracker esophagus is one of primary esophageal motility disorders. Nutcracker esophagus is defined as normal peristalsis of the esophageal body with an average distal esophageal amplitude exceeding 180 mm Hg and often has non-cardiac chest pain or dysphagia. Barium swallows are usually normal but a corkscrew-like esophagus, reminiscent of the findings of diffuse esophageal spasm (DES), is observed occasionally.
3. Hypertensive lower esophageal sphincter (Hypertensive LES)
This esophageal motility disorder is characterized by elevation of LES pressure, causing chest pain and dysphagia. A mean resting LES static pressure of ≥45 mmHg, normal relaxation of the LES, and normal peristaltic waves of the esophageal body are essential for diagnosis of this disorder.
4. Non-specific esophageal motility disorder (NEMD) (Fig.  21)
NEMD represents a spectrum of esophageal motility abnormalities presenting with apparent esophageal manometric tests, but failing to meet the diagnostic criteria for the esophageal manometric features of achalasia, DES, nutcracker esophagus or hypertensive LES. The most common manometric finding among the esophageal motility abnormalities is the occurrence of low contraction waves with amplitudes of ≤30 mmHg or nonpropagating contractions in the lower esophagus. According to the latest classification of esophageal manometry, detection of the above manometric finding on water swallowing at a frequency of ≥30% is newly defined as ineffective esophageal motility (IEM).
5. Esophageal motility dysfunctions complicating other diseases
Esophageal motility dysfunction may be associated with collagen diseases such as scleroderma and systemic lupus erythematosus, diabetes mellitus, amyloidosis, eosinophilic esophagitis, neurodegenerative disorders such as Parkinson’s disease, and alcohol dependence.
6. Pseudoachalasia
This disorder presents with apparently achalasia-like symptoms/findings associated with malignancy, such as carcinoma of the esophagogastric junction.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Iwakiri K, Hoshihara Y, Kawami N, et al. The appearance of rosette-like esophageal folds(“esophageal rosette”)in the lower esophagus after a deep inspiration is a characteristic endoscopic finding of primary achalasia. J Gastroenterol. 2010;45(4):422–5.CrossRefPubMed Iwakiri K, Hoshihara Y, Kawami N, et al. The appearance of rosette-like esophageal folds(“esophageal rosette”)in the lower esophagus after a deep inspiration is a characteristic endoscopic finding of primary achalasia. J Gastroenterol. 2010;45(4):422–5.CrossRefPubMed
2.
Zurück zum Zitat Camacho-Lobato L, Katz PO, Eveland J, et al. Vigorous achalasia: original description requires minor change. J Clin Gastroenterol. 2001;33(5):375–7.CrossRefPubMed Camacho-Lobato L, Katz PO, Eveland J, et al. Vigorous achalasia: original description requires minor change. J Clin Gastroenterol. 2001;33(5):375–7.CrossRefPubMed
3.
Zurück zum Zitat Hongo M. The effects of calcium-antagonists on lower esophageal sphincter pressure-the possibility of application of nifedipine to achalasia. J Jpn Soc Gastroenterol. 1982;79(10):1883–91. Hongo M. The effects of calcium-antagonists on lower esophageal sphincter pressure-the possibility of application of nifedipine to achalasia. J Jpn Soc Gastroenterol. 1982;79(10):1883–91.
4.
Zurück zum Zitat Becker BS, Burakoff R. The effect of verapamil on the lower esophageal sphincter pressure in normal subjects and in achalasia. Am J Gastroenterol. 1983;78(12):773–5.PubMed Becker BS, Burakoff R. The effect of verapamil on the lower esophageal sphincter pressure in normal subjects and in achalasia. Am J Gastroenterol. 1983;78(12):773–5.PubMed
5.
Zurück zum Zitat Wong RK, Maydonovitch C, Garcia JE, et al. The effect of terbutaline sulfate, nitroglycerin, and aminophylline on lower esophageal sphincter pressure and radionuclide esophageal emptying in patients with achalasia. J Clin Gastroenterol. 1987;9(4):386–9.CrossRefPubMed Wong RK, Maydonovitch C, Garcia JE, et al. The effect of terbutaline sulfate, nitroglycerin, and aminophylline on lower esophageal sphincter pressure and radionuclide esophageal emptying in patients with achalasia. J Clin Gastroenterol. 1987;9(4):386–9.CrossRefPubMed
6.
Zurück zum Zitat Coccia G, Borttolotti M, Michetti P, et al. Prospective clinical and manometric study comparing pneumatic dilatation and sublingual nifedipine in the treatment of oesophageal achalasia. Gut. 1991;32(6):604–6.CrossRefPubMedPubMedCentral Coccia G, Borttolotti M, Michetti P, et al. Prospective clinical and manometric study comparing pneumatic dilatation and sublingual nifedipine in the treatment of oesophageal achalasia. Gut. 1991;32(6):604–6.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Short TP, Thomas E. An overview of the role of calcium antagonists in the treatment of achalasia and diffuse oesophageal spasm. Drug. 1992;43(2):177–84.CrossRef Short TP, Thomas E. An overview of the role of calcium antagonists in the treatment of achalasia and diffuse oesophageal spasm. Drug. 1992;43(2):177–84.CrossRef
8.
Zurück zum Zitat Harasawa S. Manual for treatment of chronic diseases. Achalasia. Clinic All-Round. 1997;46:1059–62. Harasawa S. Manual for treatment of chronic diseases. Achalasia. Clinic All-Round. 1997;46:1059–62.
9.
Zurück zum Zitat Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50(6):758–64.CrossRefPubMedPubMedCentral Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50(6):758–64.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kaufman JA, Oelschlager BK. Treatment of achalasia. Curr Treat Opinions Gastroenterol. 2005;8(1):59–69.CrossRef Kaufman JA, Oelschlager BK. Treatment of achalasia. Curr Treat Opinions Gastroenterol. 2005;8(1):59–69.CrossRef
11.
Zurück zum Zitat Tanaka Y, Iwakiri K, Kawami N, et al. Predictors of a better outcome of pneumatic dilatation in patients with primary achalasia. J Gastroenterol. 2010;45(2):153–8.CrossRefPubMed Tanaka Y, Iwakiri K, Kawami N, et al. Predictors of a better outcome of pneumatic dilatation in patients with primary achalasia. J Gastroenterol. 2010;45(2):153–8.CrossRefPubMed
12.
Zurück zum Zitat Boeckxstaens GE, Annese V, des Varannes SB, et al. European Achalasia Trial Investigators. Pneumatic dilation versus laparoscopic Heller’s myotomy for idiopathic achalasia. N Engl J Med. 2011;364(19):1807–16.CrossRefPubMed Boeckxstaens GE, Annese V, des Varannes SB, et al. European Achalasia Trial Investigators. Pneumatic dilation versus laparoscopic Heller’s myotomy for idiopathic achalasia. N Engl J Med. 2011;364(19):1807–16.CrossRefPubMed
13.
Zurück zum Zitat Richter JE, Boeckxstaens GE. Management of achalasia: surgery or pneumatic dilation. Gut. 2011;60(6):869–76.CrossRefPubMed Richter JE, Boeckxstaens GE. Management of achalasia: surgery or pneumatic dilation. Gut. 2011;60(6):869–76.CrossRefPubMed
14.
Zurück zum Zitat Zaninotto G, Annese V, Costantini M, et al. Randomized controlled trial of botulinum toxin versus laparoscopic Heller myotomy for esophageal achalasia. Ann Surg. 2004;239(3):364–70.CrossRefPubMedPubMedCentral Zaninotto G, Annese V, Costantini M, et al. Randomized controlled trial of botulinum toxin versus laparoscopic Heller myotomy for esophageal achalasia. Ann Surg. 2004;239(3):364–70.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Mikaeli J, Yaghoobi M, Montazeri G, et al. Efficacy of botulinum toxin injection before pneumatic dilatation in patients with idiopathic achalasia. Dis Esophagus. 2004;17(3):213–7.CrossRefPubMed Mikaeli J, Yaghoobi M, Montazeri G, et al. Efficacy of botulinum toxin injection before pneumatic dilatation in patients with idiopathic achalasia. Dis Esophagus. 2004;17(3):213–7.CrossRefPubMed
16.
Zurück zum Zitat Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy(POEM)for esophageal achalasia. Endoscopy. 2010;42(4):265–71.CrossRefPubMed Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy(POEM)for esophageal achalasia. Endoscopy. 2010;42(4):265–71.CrossRefPubMed
17.
Zurück zum Zitat Makuuchi H, Mitomi T, Sasaki T, et al. Diagnosis and treatment for esophageal achalasia. The Japanese. J Thorac Cardiovasc Surg. 1988;36(5):737–9. Makuuchi H, Mitomi T, Sasaki T, et al. Diagnosis and treatment for esophageal achalasia. The Japanese. J Thorac Cardiovasc Surg. 1988;36(5):737–9.
18.
Zurück zum Zitat Mitomi T, Makuuchi H. Functional disorders. Surgery for esophagus. Shin Gekagaku Taikei 21, Nakayama-shoten, Tokyo, pp 353–96;1988. Mitomi T, Makuuchi H. Functional disorders. Surgery for esophagus. Shin Gekagaku Taikei 21, Nakayama-shoten, Tokyo, pp 353–96;1988.
19.
Zurück zum Zitat Kostic S, Kjellin A, Ruth M, et al. Pneumatic dilatation or laparoscopic cardiomyotomy in the management of newly diagnosed idiopathic achalasia. Results of a randomized controlled trial. World J Surg. 2007;31(3):470–8.CrossRefPubMed Kostic S, Kjellin A, Ruth M, et al. Pneumatic dilatation or laparoscopic cardiomyotomy in the management of newly diagnosed idiopathic achalasia. Results of a randomized controlled trial. World J Surg. 2007;31(3):470–8.CrossRefPubMed
20.
Zurück zum Zitat Lopushinsky SR, Urbach DR. Pneumatic dilatation and surgical myotomy for achalasia. JAMA. 2006;296(18):2227–33.CrossRefPubMed Lopushinsky SR, Urbach DR. Pneumatic dilatation and surgical myotomy for achalasia. JAMA. 2006;296(18):2227–33.CrossRefPubMed
21.
Zurück zum Zitat Palanivelu C, Maheshkumar GS, Jani K, et al. Minimally invasive management of achalasia cardia: results from a single center study. JSLS. 2007;11(3):350–7.PubMedPubMedCentral Palanivelu C, Maheshkumar GS, Jani K, et al. Minimally invasive management of achalasia cardia: results from a single center study. JSLS. 2007;11(3):350–7.PubMedPubMedCentral
22.
Zurück zum Zitat Wang L, Li YM, Li L. Meta-analysis of randomized and controlled treatment trials for achalasia. Dig Dis Sci. 2009;54(11):2303–11.CrossRefPubMed Wang L, Li YM, Li L. Meta-analysis of randomized and controlled treatment trials for achalasia. Dig Dis Sci. 2009;54(11):2303–11.CrossRefPubMed
23.
Zurück zum Zitat Zaninotto G, Costantini M, Rizzetto C, et al. Four hundred laparoscopic myotmies for esophageal achalasia: a single centre experience. Ann Surg. 2008;248(6):986–93.CrossRefPubMed Zaninotto G, Costantini M, Rizzetto C, et al. Four hundred laparoscopic myotmies for esophageal achalasia: a single centre experience. Ann Surg. 2008;248(6):986–93.CrossRefPubMed
24.
Zurück zum Zitat Jeansonne LO, White BC, Pilger KE, et al. Ten-year follow-up of laparoscopic Heller myotomy for achalasia shows durability. Surg Endosc. 2007;21(9):1498–502.CrossRefPubMed Jeansonne LO, White BC, Pilger KE, et al. Ten-year follow-up of laparoscopic Heller myotomy for achalasia shows durability. Surg Endosc. 2007;21(9):1498–502.CrossRefPubMed
25.
Zurück zum Zitat Esophageal motility testing made easy. Bremner CG, DeMeester TR, Bremner RM, Mason RJ, eds. Quality Medical Publishing, ST. Louis, Missouri, 2001. Esophageal motility testing made easy. Bremner CG, DeMeester TR, Bremner RM, Mason RJ, eds. Quality Medical Publishing, ST. Louis, Missouri, 2001.
26.
Zurück zum Zitat Kusano M, Maeda M, Shimoyama Y, et al. Esophageal motor function in nonachalasia motility disorders. J Jpn Soc Gastroenterol. 2003;100(9):1095–105. Kusano M, Maeda M, Shimoyama Y, et al. Esophageal motor function in nonachalasia motility disorders. J Jpn Soc Gastroenterol. 2003;100(9):1095–105.
27.
Zurück zum Zitat Kashiwagi H, Omura N. Each argument 1. Benign diseases 2. Function and abnormal structure. Shokudogeka up-to-date, Kuwano H eds, Chugai Medical co, Tokyo, p 40–55;2010. Kashiwagi H, Omura N. Each argument 1. Benign diseases 2. Function and abnormal structure. Shokudogeka up-to-date, Kuwano H eds, Chugai Medical co, Tokyo, p 40–55;2010.
28.
Zurück zum Zitat Clouse RE, Staiano A. Contraction abnormalities of the esophageal body in patients referred for manometry. Dig Dis Sci. 1983;28(9):784–91.CrossRefPubMed Clouse RE, Staiano A. Contraction abnormalities of the esophageal body in patients referred for manometry. Dig Dis Sci. 1983;28(9):784–91.CrossRefPubMed
29.
Zurück zum Zitat Kahrilas PJ, Dodds WJ, Hogan WJ. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology. 1988;94(1):73–80.CrossRefPubMed Kahrilas PJ, Dodds WJ, Hogan WJ. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology. 1988;94(1):73–80.CrossRefPubMed
30.
Zurück zum Zitat Leite LP, Johnston BT, Barrett J, et al. Ineffective esophageal motility(IEM):the primary finding in patients with non-specific esophageal motility disorder. Dig Dis Sci. 1997;42(9):1859–65.CrossRefPubMed Leite LP, Johnston BT, Barrett J, et al. Ineffective esophageal motility(IEM):the primary finding in patients with non-specific esophageal motility disorder. Dig Dis Sci. 1997;42(9):1859–65.CrossRefPubMed
Metadaten
Titel
Descriptive Rules for Achalasia of the Esophagus, June 2012: 4th Edition
verfasst von
Japan Esophageal Society
Publikationsdatum
05.09.2017
Verlag
Springer Japan
Erschienen in
Esophagus / Ausgabe 4/2017
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-017-0589-1

Weitere Artikel der Ausgabe 4/2017

Esophagus 4/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.